GlobeNewswire

NYNJA Announces Plans for First Blockchain-Enabled International Messaging App with Integrated Digital Marketplace and its own Cryptocurrency Economy

Dela

Cross-platform App Enables Consumers and Enterprise Users to Communicate, Buy, Sell and Trade without Language Barriers in a Decentralized Cryptocurrency Marketplace

NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- NYNJA Group Ltd. (https://www.nynja.biz/), a global communications and mobile technology company, today announced NYNJA, the first international communications app with a built-in digital marketplace and cryptocurrency wallet. NYNJA is a cross-platform app that combines voice, text and visual messaging with robust and secure business management and e-commerce features, all powered by its own financial ecosystem and cryptocurrency, NYNJACoin. NYNJA, in development since Q1 2017, is currently in beta and the public token sale for NYNJACoin will launch on April 17, 2018.

"While there is no shortage of mobile messaging apps, there has never been an all-in-one communications app that seamlessly supports the messaging and transactional needs of both individual and business users with the utmost security protocols available today," said co-founder and CEO Salvatore Guerrieri. "NYNJA is the first app of its kind to harness the full potential of its user base, empowering them with a cross-platform multimedia messaging app and a built-in global marketplace backed by secure Blockchain protocols."

The NYNJA marketplace allows users to buy and sell goods and services internationally through an open API using NYNJACoin, the ERC20 standard cryptocurrency of NYNJA's integrated financial ecosystem. With NYNJACoin, users can also access exclusive groups and pay for proprietary in-group content such as licensed assets or timed consultations. Users can also earn NYNJACoin for viewing ads and sharing branded material like sticker-packs or coupons. Each account can be organized according to the user's social, consumer and business lives, and comes with a secure Ethereum wallet enabling users to transact freely within the app for fast international payment transfers without the need for costly external payment providers or internal platform fees. Completely scalable, the open-source platform will enable developers to build into NYNJA with the addition of value-add applications.

In addition to standard messaging features, NYNJA features scheduled messaging and translation. NYNJA is global, integrated and secure across every platform and device, and lets users make free Internet calls and transfer calls to any phone. NYNJA's architecture features secure encryption of cloud data storage for saving messages, images and files, and features a beautifully designed and intuitive interface highlighted by the app's patent-pending concentric wheel navigation system. The concentric wheel enables quick and easy navigation of the app using only one thumb and eliminates the use for back buttons.

"More than a quarter of the world uses mobile messaging apps, but the current class of apps falls short because they are either global but too basic, for example WhatsApp and Facebook Messenger, or have adoption limitations due to being region-specific as in the case of Line and WeChat," said NYNJA co-founder and president Alejandro Gramont. "Furthermore, many messaging apps are geared primarily for personal and social use rather than business; and most business-class apps lack the capabilities required to truly qualify them as enterprise-grade. NYNJA is in a class of its own as the only all-encompassing, highly customizable communications app with a blockchain-based marketplace and financial ecosystem."

At launch the NYNJA app will be available on Android, iOS, and Web with native development of Mac, Linux and Windows versions to follow.

NYNJA's experienced team includes CEO and global entrepreneur, Salvatore Guerrieri; co-founder, president and COO Alejandro Gramont; chief technology officer, Plamen Minev and co-founder and chief strategy officer Marshall Taplits. Advisors include Michael Terpin, CEO of investor conference series, CoinAgenda; Ken Lo, CEO of ANX International, which is a leading service provider of blockchain payment solutions; and Howard Bilton, founder of The Sovereign Group. Miles Pelham, founder of Digitas Limited and Mun Shing Cheong, the general manager of ANX Digital, are also advisors.

For more information about NYNJA Group Limited, please visit: https://www.nynja.biz/.

Learn more about the NYNJACoin ICO at https://nynjacoinusa.com/.

About NYNJA
NYNJA Group Limited is a Hong Kong-based company creating the first international cross-platform communications app with a built-in cryptocurrency marketplace and crypto wallet. The NYNJA app combines voice, text and visual messaging with robust business management and e-commerce features, all powered by its own financial ecosystem and cryptocurrency, NYNJACoin. With NYNJACoin, users can exchange freelance services and virtual goods, as well as access exclusive content and earn tokens for viewing ads or using branded material.

For more information on the NYNJA app and token sale, please visit: https://www.nynja.biz/.

Media Contact:

Transform Group, nynja@transform.pr  

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8d324656-a32a-4b7a-8dfb-a09ebb3e719f




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NYNJA via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum